ArticlePDF Available

International Journal of Ayurveda and Pharma Research STUDIES OF BRAHMI BASED UNANI COMPOUND FORMULATION ON AUTISM TO ASSESS ITS EFFICACY

Authors:

Abstract and Figures

Autism is most common neurodevelopmental disorder seen in pediatric population. The ratio of autism spectrum disorder nowadays increasing day by day according to Indian statistical data. In autism child generally have poor socialization, communication and speech issue which is normal in few months of the age and start regress in second years of life. In field of rehabilitation autism has better results by occupational therapy, speech therapy and early intervention. In this study we tried the Centella asiatica extract in form of Brahmi to treat many clinical symptoms such as cognition, poor attention span, hyperactivity, not responding name in autistic children. The outcome measure Childhood Autism Rating Scale and Vineland Social Maturity Scale were used for pre and post test assessment and after the statistical analysis the result suggested that experimental group have more significance result that is p< 0.01 in experimental group than control group that is p<0.09. It also suggested that score of CARS and VSMS show maximum change by employing Brahmi with other rehabilitation intervention in autistic kids.
Content may be subject to copyright.
ISSN: 2322 - 0902 (P)
ISSN: 2322 - 0910 (O)
IJAPR | May 2017 | Vol 5 | Issue 5
62
International Journal of Ayurveda
and Pharma Research
Research Article
STUDIES OF BRAHMI BASED UNANI COMPOUND FORMULATION ON AUTISM TO ASSESS ITS
EFFICACY
Arun Mukherjee1*, Meena Gupta1, Shruti Dogra1, Sumit Sinha2, Yasmeen Shamsi3
*1UDAAN-for the Disabled, Lajpat Nagar, New Delhi, India.
2Foundation for Spastic and Mentally Handicapped Persons (FSMHP), UDAAN, New Delhi, India.
3Jamia Hamdard University, New Delhi, India.
ABSTRACT
Autism is most common neurodevelopmental disorder seen in pediatric population. The ratio of autism
spectrum disorder nowadays increasing day by day according to Indian statistical data. In autism child
generally have poor socialization, communication and speech issue which is normal in few months of the
age and start regress in second years of life. In field of rehabilitation autism has better results by
occupational therapy, speech therapy and early intervention. In this study we tried the Centella asiatica
extract in form of Brahmi to treat many clinical symptoms such as cognition, poor attention span,
hyperactivity, not responding name in autistic children. The outcome measure Childhood Autism Rating
Scale and Vineland Social Maturity Scale were used for pre and post test assessment and after the statistical
analysis the result suggested that experimental group have more significance result that is p< 0.01 in
experimental group than control group that is p<0.09. It also suggested that score of CARS and VSMS show
maximum change by employing Brahmi with other rehabilitation intervention in autistic kids.
KEYWORDS: Autism, Barcoppa, Cognition, Neurodevelopmental delayed.
INTRODUCTION
Autism in this era is the most common
developmental disorder seen in pediatric population. It is
associated with impaired both verbal and nonverbal
communication, reciprocal social interactions poor
interaction with peer groups, poor socialization, self-
occupancy and poor social skills. In autism most children
reach their development milestone according to their
normal age and then regress[1]. Autism is caused by a
combination of genetic and environmental factors[2].
According to diagnostic and statistical manual of mental
health IV (DSM) autism comes under the autism spectrum
disorders where there is lacks in cognitive and language
development. According to statistical data of center for
disease control and prevention (CDC), every one child has
autism out of 68 children[3]. Brahmi is one of a group of
plant extracts obtained from the plant: Centella asiatica
(Linn.) Urban, which has been used extensively as memory
enhancer and brain repairer by Ayurveda Physicians. It
has a quality to regeneration and enhancement of brain
repair. The name, Brahmi, is named after one of the highest
states of consciousness (Brahman or God of
consciousness), Brahmi (Centella asiatica or Gotu Kola) is
one of the most powerful brain tonics in the Ayurvedic
medicine. It supports restful sleep, calms emotional
turbulence, and simultaneously improves concentration
and alertness. In cognitive enhancement area specially in
case of autism, these children have very good visual
cognition seen in autism according to research by
university Norkinptom, UK. This study is conducted on
autism spectrum children for see the changes in their
cognitive and quality of life by employing Brahmi
medication.
Materials and methods
Subjects
Diagnosed cases of Autism spectrum disorders
referred by clinical psychologist according to childhood
rating scale (CARs), autism treatment evaluation checklist
(ATEC) and Vinland social maturity scales (VSMS) were
used by the clinical psychologist to diagnosed the case for
Brahami treatment and on those subjects who comes
under the norms of selection criteria. The inclusion criteria
were Children diagnosed as Autism using the DSM IV or V
Autism Criteria, certified to be in adequate healthy state by
panel Pediatrician or Physician, age group 2 to 10 years
and of either sex, well-educated parents who can
understand the experimental nature of the study, and can
give informed voluntary written permission for inclusion
of their autistic child for this study. The exclusion criteria
were as followed children having any genetic disabilities
or cerebral palsy, insufficiency of liver / kidney / marrow
functions as per appropriate biochemical tests, chronic
uncontrolled illness that may need medical therapy which
could interfere with diagnosis, treatment and assessment
of the Autism symptoms.
Methods
Before recruiting the subjects inform consent
form the parent of selected children were collected. The
duration and process of Brahmi treatment explained to the
parent whose children enrolled in the ongoing study. The
duration of Bhrami medication was three month after
enrollment of the subject in the study. All biochemical
testing were performing to justify the normal health
condition before starting the Brahmi treatment.
Int. J. Ayur. Pharma Research, 2017;5(5):62-64
Available online at: http://ijapr.in
63
The composition of Brahmi medicines includes Centella
asiatica, Piper nigrum, Prunus amygdalus, Emblica
officinalis, phoenix dactylifera and delphinium denudatum
wall which is already provided by CCRU to the UDAAN for
the treatment purpose. Dose of the Brahmi medicine
depends on the weight of per child which is shown as in
table -1.
Table 1: Dosage of Brahmi according to weight of the child
S. No
Weight
Dose for Brahmi
1
10-20Kg
2.5ml morning
2.5 ml evening
2
20-30Kg
2.5ml morning
5ml evening
3
30-40Kg
5ml morning
5ml evening
4
40-50Kg
5ml morning
7.5 ml evening
5
50-60Kg
7.5ml morning
7.5ml evening
6
Above 60Kg
10ml morning
10ml evening
In this study the subjects recruited between the
age group 2 to 10 years proved to have autism according
to criteria DSM-IV and CARS scoring. Total twenty subject
who comes under the inclusion and exclusion criteria were
divided into two groups named as Experimental group
(EG) and control group (CG) for the Brahmi medication
treatment. Before stating the Brahmi treatment pre
assessment called pretest data and after the completion of
3 month Brahmi treatment called post assessment data
were conducted to collect the data for statistical analysis
using the following outcome measures such as Vineland
Social Maturity Scale (VSMS) and Childhood Autism Rating
Scale (CARS).
Outcome Measures
Childhood autism rating scale (CARs) and
Vineland Social Maturity Scale (VSMS) were used as
outcome measure for statistical analysis. CARs and VSMS
both are the internationally approved scale for the
assessment of level of autism and developmental
component in neurodevelopmental disability.
In childhood autism rating scale (CARS) [4] is a 15
item behavioral rating scale developed to identify children
with autism, and to distinguish them from
developmentally handicapped children without the autism
syndrome. CARS is especially effective in discriminating
between autistic children and trainable mentally retarded
children. It was designed to help differentiate children
with autism from those with other developmental delays,
such as intellectual disability.
Vineland Social Maturity Scale (VSMS) [5] is a
uniquely useful instrument for assessing social maturity of
children and young adults. It is used for measure many
domains such as mental status social maturity and
developmental milestone in may neurodevelopmental
disorders such as cerebral palsy, down syndrome and
autism.
RESULT
After the statistical data analysis using SPSS 20.0
(Armonk, NY, IBM Corp.USA) and Microsoft Excel 2010.
The results show significant improvement in both the
groups (CG and EG) as shown in table-2. The result also
show more significant results in EG that is p<0.01as
compare to CG that is p<0.09, where p-value of less that
0.05 is considered statistically significant.
Table-2. Descriptive Data of Control and Experimental Groups after Statistical Analysis
Mean + SD
Pre
Post
Pre
Post
Mean Change
P-Value
Control Group
36.28
50.02
31.50+3.26
34.78+12.72
3.28
0.09
Experimental Group
33.56
46.5
31.50+2.52
19.79+17.91
11.71
0.01*
*p-value<0.05 is taken as significant
In EG mean change score are 11.71 as compare to
CG that is 3.28 which also show significant changes in EG
and shows that Brahmi medication with occupational
therapy helps in improvement of social skill as well as
cognitive changes in autistic children. It also suggested
that the rate of progress of improvement can be improved
by using Brahmi medication along with occupational
therapy rather than only occupational therapy alone.
DISCUSSION AND CONCLUSION
Now a day study of natural and herbal products
used in traditionally medicine increasing day by day.
Brahmi is one of the herbal medicines which are more
popular for cognitive enhancement [6] and coronary heart
disease management[7]. If we talk about autism, these
children have very good visual cognition but there is need
to stimulate it in prospective and purposive manner.
Brahmi medication has good results in cognitive
enhancement in many diseases such as human memory [8-
9]. We concluded that from our result Brahmi medication
along with conservative treatment approached such as
occupational therapy, play therapy and early intervention
may enhances the rate of progress in quality of life (QOL)
of autistic kids. In future this medicine can play important
role to make these kinds in inclusion training schools also.
ACKNOWLEDGE
This work was supported by grant from Central
Council for Research in Unani Medicine, Department of
Ayush, Ministry of Health, and Government of India (GOI).
The author also wants to thanks to all parent and child
who participated in this study.
Arun Mukherjee et al. Brahmi Based Unani Compound Formulation on Autism to Assess its Efficacy
IJAPR | May 2017 | Vol 5 | Issue 5
64
REFERENCES
1. Stefanatos GA. "Regression in autistic spectrum
disorders". Neuropsychol Rev. 2008; 18(4): 305319.
doi:10.1007/s11065-008-9073-y. PMID 18956241.
2. Rutter M. "Incidence of autism spectrum disorders:
changes over time and their meaning". Acta Paediatr.
2005 94 (1): 215. doi:10.1111/j.1651-2227.2005.
tb01779.x. PMID 15858952.
3. Lord C, Risi S, DiLavore PS, Shulman C, Thurm A,
Pickles A. “ Autism from 2 to 9 years of age”. Arch Gen
Psychiatry. 2006;63(6):694-701.
4. Chlebowski C, Green JA, Bartom MA, Fein D. “Using
the childhood autism rating scale to diagnose autism
spectrum disorders”. J Autism Dev Disord, 2013;
40(7): 787-799.
5. Doll, E. A. "Annotated bibliography on the Vineland
Social Maturity Scale.". Journal of Consulting
Psychology. 1940; 4 (4): 123132.
6. Bandyopadhyay M, Chakraborty R, Raychaudhuri U.
“Antioxidant activity of natural plants sources in
dairy dessert under thermal treatment. Food sci
technol. 2008; 41(1) ; 816-825.
7. Srimachai S, Sylvie D, Celine D, Sarawut K, Nina DU et
al “Bocopa monnieri extract increases rat coronary
flow and protects against myocardial ischemia/
reperfusion injury”. BMC, Complementary and
alternative medicine. 2017; 17(117); 2-10.
8. Steven R, Dianne B, Sonia B. “Chronic effects of
brahmi (Bacopa monnieri) on human memory”.
Neuropsychopharmacology, 2002; 27; 279-281.
9. Piyabhan P, Wetchateng T “Bacopa monnieri
(Brahmi) enhanced cognitive function and prevented
cognitive impairment by increasing VGLUT2
immunodensity in prefrontal cortex of sub-chronic
phencyclidine rat model of schizophrenia”. J Med
Assoc Thai. 2015; 98(3): S7-15.
Cite this article as:
Arun Mukherjee, Meena Gupta, Shruti Dogra, Sumit Sinha, Yasmeen Shamsi.
Studies of Brahmi Based Unani Compound Formulation on Autism to Assess
its Efficacy. International Journal of Ayurveda and Pharma Research.
2017;5(5):62-64.
Source of support: Nil, Conflict of interest: None Declared
*Address for correspondence
Arun Mukherjee
UDAAN-for the Disabled, Lajpat
Nagar, New Delhi- 110024, India.
Email: arun@udaan.org
Phone: 9811157839
... Centella asiatica aids in antiepileptic activity by reducing motor activity [15], restores level of growth stimulating hormone [16], enhances neuronal dendrite in stress and memory disorder [17]. It has been used as a memory enhancing, strength promoting, immune booster, anti-anxiety, antiepilepsy and anti-stress substance since ancient times [18,19]. ...
Article
Full-text available
Medicinal plants have been used since ancient times for the treatment of a range of diseases. Nowadays medicinal plants have attained a significant role in health system all over the world for both humans and animals not only in the diseased condition but also as potential material for maintaining proper health. In this era, focus on plant research has increased all over the world and a large body of evidence has been accumulated to highlight the immense potential of medicinal plants used in various traditional systems of medicine. Amongst various medicinal plants Brahmi (Centella asiatica Linn.) is one of the most useful plants seen in Unani system of medicine. Centella asiatica Linn. is an imperative medicinal drug which possesses significant medicinal properties, especially those involving cognition. It has been extensively used In Unani system of medicine, as Muqawwi-e-Dimagh (brain tonic), Muqawwi-e-Asab (nervine tonic) and Musakkin-e-Asab (tranquiliser) drug in various neuro-psychiatric disorders e.g. Zof-e-Dimagh (cerebral asthenia), Zof-e-Asab (neuroasthenia), Zof-e-Hafiza (poor memory), Nisyan (amnesia), Junoon (insanity), Akhtanaqur Rahem (Hysteria) The present paper reviews Brahmi (Centella asiatica Linn.) as a medicinal plant and highlights its benefits in various health problems.
Article
Full-text available
Medicinal plants have been used since ancient times for the treatment of a range of diseases. Nowadays medicinal plants have attained a significant role in health system all over the world for both humans and animals not only in the diseased condition but also as potential material for maintaining proper health. In this era, focus on plant research has increased all over the world and a large body of evidence has been accumulated to highlight the immense potential of medicinal plants used in various traditional systems of medicine. Amongst various medicinal plants Brahmi (Centella asiatica Linn.) is one of the most useful plants seen in Unani system of medicine. Centella asiatica Linn. is an imperative medicinal drug which possesses significant medicinal properties, especially those involving cognition. It has been extensively used In Unani system of medicine, as Muqawwi-e-Dimagh (brain tonic), Muqawwi-e-Asab (nervine tonic) and Musakkin-e-Asab (tranquiliser) drug in various neuro-psychiatric disorders e.g. Zof-e-Dimagh (cerebral asthenia), Zof-e-Asab (neuroasthenia), Zof-e-Hafiza (poor memory), Nisyan (amnesia), Junoon (insanity), Akhtanaqur Rahem (Hysteria) The present paper reviews Brahmi (Centella asiatica Linn.) as a medicinal plant and highlights its benefits in various health problems.
Article
Full-text available
Background This study explored Bacopa monnieri, a medicinal Ayurvedic herb, as a cardioprotectant against ischemia/reperfusion injury using cardiac function and coronary flow as end-points. Methods In normal isolated rat hearts, coronary flow, left ventricular developed pressure, heart rate, and functional recovery were measured using the Langendorff preparation. Hearts were perfused with either (i) Krebs-Henseleit (normal) solution, (control), or with 30, 100 μg/ml B. monnieri ethanolic extract (30 min), or (ii) with normal solution or extract for 10 min preceding no-perfusion ischemia (30 min) followed by reperfusion (30 min) with normal solution. Infarct volumes were measured by triphenyltetrazolium staining. L-type Ca2+-currents (ICa, L) were measured by whole-cell patching in HL-1 cells, a mouse atrial cardiomyocyte cell line. Cytotoxicity of B. monnieri was assessed in rat isolated ventricular myocytes by trypan blue exclusion. ResultsIn normally perfused hearts, B. monnieri increased coronary flow by 63 ± 13% (30 μg/ml) and 216 ± 21% (100 μg/ml), compared to control (5 ± 3%) (n = 8–10, p < 0.001). B. monnieri treatment preceding ischemia/reperfusion improved left ventricular developed pressure by 84 ± 10% (30 μg/ml), 82 ± 10% (100 μg/ml) and 52 ± 6% (control) compared to pre- ischemia/reperfusion. Similarly, functional recovery showed a sustained increase. Moreover, B. monnieri (100 μg/ml) reduced the percentage of infarct size from 51 ± 2% (control) to 25 ± 2% (n = 6-8, p < 0.0001). B. monnieri (100 μg/ml) reduced ICa, L by 63 ± 4% in HL-1 cells. Ventricular myocyte survival decreased at higher concentrations (50–1000 μg/ml) B. monnieri. ConclusionsB. monnieri improves myocardial function following ischemia/reperfusion injury through recovery of coronary blood flow, contractile force and decrease in infarct size. Thus this may lead to a novel cardioprotectant strategy.
Article
Full-text available
Autism represents an unusual pattern of development beginning in the infant and toddler years. To examine the stability of autism spectrum diagnoses made at ages 2 through 9 years and identify features that predicted later diagnosis. Prospective study of diagnostic classifications from standardized instruments including a parent interview (Autism Diagnostic Interview-Revised [ADI-R]), an observational scale (Pre-Linguistic Autism Diagnostic Observation Schedule/Autism Diagnostic Observation Schedule [ADOS]), and independent clinical diagnoses made at ages 2 and 9 years compared with a clinical research team's criterion standard diagnoses. Three inception cohorts: consecutive referrals for autism assessment to (1) state-funded community autism centers, (2) a private university autism clinic, and (3) case controls with developmental delay from community clinics. At 2 years of age, 192 autism referrals and 22 developmentally delayed case controls; 172 children seen at 9 years of age. Consensus best-estimate diagnoses at 9 years of age. Percentage agreement between best-estimate diagnoses at 2 and 9 years of age was 67, with a weighted kappa of 0.72. Diagnostic change was primarily accounted for by movement from pervasive developmental disorder not otherwise specified to autism. Each measure at age 2 years was strongly prognostic for autism at age 9 years, with odds ratios of 6.6 for parent interview, 6.8 for observation, and 12.8 for clinical judgment. Once verbal IQ (P = .001) was taken into account at age 2 years, the ADI-R repetitive domain (P = .02) and the ADOS social (P = .05) and repetitive domains (P = .005) significantly predicted autism at age 9 years. Diagnostic stability at age 9 years was very high for autism at age 2 years and less strong for pervasive developmental disorder not otherwise specified. Judgment of experienced clinicians, trained on standard instruments, consistently added to information available from parent interview and standardized observation.
Article
Background: Glutamatergic hypofunction is affected in schizophrenia. The decrement ofpresynaptic glutamatergic marker remarkably vesicular glutamate transporter type 1 (VGLUT1) indicates the deficit ofglutamatergic and cognitive function in schizophrenic brain. However there have been afew studies in VGLUT2. Brahmi, a traditional herbal medicine, might be a new frontier of cognitive deficit treatment and prevention in schizophrenia by changing cerebral VGLUT2 density. Objective: To study cognitive enhancement- and neuroprotective-effects of Brahmi on novel object recognition task and cerebral VGLUT2 immunodensity in sub-chronic phencyclidine (PCP) rat model of schizophrenia. Material and method: Cognitive enhancement effect study; rats were assigned to three groups; Group-1: Control, Group-2: PCP administration and Group-3: PCP + Brahmi. Neuroprotective effect study; rats were assigned to three groups; Group-1: Control, Group-2: PCP administration and Group-3: Brahmi + PCP Discrimination ratio (DR) representing cognitive ability was obtained from novel object recognition task. VGLUT2 immunodensity was measured in prefrontal cortex, striatum, cornu ammonis fields 1 (CA1) and 2/3 (CA2/3) of hippocampus using immunohistochemistry. Results: DR was significantly reduced in PCP group compared with control. This occurred alongside VGLUT2 reduction in prefrontal cortex, but not in striatum, CA1 or CA2/3. Both PCP + Brahmi and Brahmi + PCP groups showed an increased DR score up to normal, which occurred alongside a significantly increased VGLUT2 immunodensity in the prefrontal cortex, compared with PCP group. Conclusion: The decrement of VGLUT2 density in prefrontal cortex resulted in cognitive deficit in rats receiving PCP. Interestingly, receiving Brahmi after PCP administration can restore this cognitive deficit by increasing VGLUT2 density in prefrontal cortex. This investigation is defined as Brahmi's cognitive enhancement effect. Additionally, receiving Brahmi before PCP administration can also prevent cognitive impairment by elevating VGLUT2 density in prefrontal cortex. This observation indicates neuroprotective effect of Brahmi. Therefore, Brahmi could be a new frontier of restoration and prevention of cognitive deficit in schizophrenia.
Article
Natural sources of antioxidant viz. beet (Beta vulgaris), mint (Mentha spicata L.) and ginger (Zingiber officinale L.) have been used to fortify sandesh (a heat desiccated product of coagulated milk protein mass called chhana which is in turn a heat and acid coagulated product of milk, analogous to cottage cheese). Three sets of experiments viz. antioxidant activity, peroxide value and ultra-violet absorbance were done to evaluate the effectiveness of natural antioxidants in reducing lipid oxidation in sandesh as compared to synthetic antioxidants like tertiary butyl hydroquinone (TBHQ), butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) under thermal treatment. Among the natural sources, ginger has the highest antioxidant activity and it was similar to TBHQ and BHA–BHT combined. Results of the antioxidant activity differed from those of the oven test at 63°C particularly for ginger and BHA–BHT combined. Control sandesh (without any antioxidants) showed the highest peroxide value and ultra-violet absorption. All the natural sources and their combinations significantly improved the oxidative stability of sandesh and their effectiveness was comparable with synthetic antioxidant TBHQ, a combination of BHA and BHT. Among the natural sources, although ginger had the highest antioxidant activity but mint showed better effectiveness in the inhibition of lipid oxidation. Regarding antioxidant activity and lipid oxidation, combination of mint or ginger with beet showed better result as compared to beet alone. Besides, sensory evaluation of freshly prepared natural source fortified sandesh samples was done as compared to control sandesh in order to commercialize the herbal sandesh in market. Sandesh containing beet, ginger, combination of beet with ginger or mint, or combination of mint with ginger were more acceptable to panelist than control sandesh.
Article
An account is given of the developmental stages in the construction and standardization of the scale. 66 bibliographical references are listed with a condensed report of each. (PsycINFO Database Record (c) 2012 APA, all rights reserved)
Article
A significant proportion of children diagnosed with Autistic Spectrum Disorder experience a developmental regression characterized by a loss of previously-acquired skills. This may involve a loss of speech or social responsitivity. but often entails both. This paper critically reviews the phenomena of regression in autistic spectrum disorders, highlighting the characteristics of regression, age of onset, temporal course, and long-term outcome. Important considerations for diagnosis are discussed and multiple etiological factors Currently hypothesized to underlie the phenomenon are reviewed. It is argued that regressive autistic spectrum disorders can be conceptualized on a spectrum with other regressive disorders that may share common pathophysiological features. The implications of this viewpoint are discussed.
Article
A study is reported on the effects of Brahmi (Bacopa monniera) on human memory. Seventy-six adults aged between 40 and 65 years took part in a double-blind randomized, placebo control study in which various memory functions were tested and levels of anxiety measured. There were three testing sessions: one prior to the trial, one after three months on the trial, and one six weeks after the completion of the trial. The results show a significant effect of the Brahmi on a test for the retention of new information. Follow-up tests showed that the rate of learning was unaffected, suggesting that Brahmi decreases the rate of forgetting of newly acquired information. Tasks assessing attention, verbal and visual short-term memory and the retrieval of pre-experimental knowledge were unaffected. Questionnaire measures of everyday memory function and anxiety levels were also unaffected.
Article
Several reviews have noted a huge increase in the rate of diagnosed autism spectrum disorders. The main aims of this paper are: 1) to use published empirical findings to consider whether the rise reflects a true increase in incidence, as distinct from the consequences of better ascertainment and a broadening of the diagnostic concept; and 2) to consider how epidemiological data may be used to test hypotheses about possible causal influences, using MMR and thimerosal as examples. Search of the literature for studies with a large epidemiological base population, systematic standardized screening, a focus on an age group for which diagnostic assessments are reliable and valid, and diagnosis by trained professionals using high-quality research assessments. Also, search of a broader literature to consider the evidence from all epidemiological studies with respect to the hypothesized causal effect of MMR and thimerosal on autism spectrum disorders. The true incidence of autism spectrum disorders is likely to be within the range of 30-60 cases per 10 000, a huge increase over the original estimate 40 years ago of 4 per 10000. The increase is largely a consequence of improved ascertainment and a considerable broadening of the diagnostic concept. However, a true risk due to some, as yet to be identified, environmental risk factor cannot be ruled out. There is no support for the hypothesis for a role of either MMR or thimerosal in causation, but the evidence on the latter is more limited. Progress in testing environmental risk hypotheses will require the integration of epidemiological and biological studies.
Using the childhood autism rating scale to diagnose autism spectrum disorders
  • C Chlebowski
  • J A Green
  • M A Bartom
  • D Fein
Chlebowski C, Green JA, Bartom MA, Fein D. "Using the childhood autism rating scale to diagnose autism spectrum disorders". J Autism Dev Disord, 2013; 40(7): 787-799.
Source of support: Nil, Conflict of interest: None Declared *Address for correspondence Arun Mukherjee UDAAN-for the Disabled
  • Arun Mukherjee
  • Meena Gupta
  • Shruti Dogra
  • Sumit Sinha
  • Yasmeen Shamsi
Cite this article as: Arun Mukherjee, Meena Gupta, Shruti Dogra, Sumit Sinha, Yasmeen Shamsi. Studies of Brahmi Based Unani Compound Formulation on Autism to Assess its Efficacy. International Journal of Ayurveda and Pharma Research. 2017;5(5):62-64. Source of support: Nil, Conflict of interest: None Declared *Address for correspondence Arun Mukherjee UDAAN-for the Disabled, Lajpat Nagar, New Delhi-110024, India. Email: arun@udaan.org Phone: 9811157839